BACKGROUND A 10-year retrospective case series was undertaken of all patients who had a tissue diagnosis of a World Health Organisation (WHO) Grade II glioma, i.e. low grade glioma (LGGM), at the Institute of Neurological Sciences (INS) between January 2010 and January 2020 (NB: pre-2016 World Health Organisation classification). The objective was to assess the correlation of World Health Organisation (WHO) Grade II gliomas to seizure symptomology, intracerebral tumour location, histopathological glioma sub-type and molecular markers including isocitrate dehydrogenase-1 (IDH-1) mutation. MATERIAL AND METHODS We extracted data regarding clinical, radiological, histological, molecular discriminators and functional outcomes in patients. The pre-operative symptomology was restricted to seizures, headache and focal neurological deficits. RESULTS 84 patients underwent resection and had a mean age of 42rs (range: 21-77yrs]). Seizures (NB: pre-2017 International League against Epilepsy classification [ILAE]) occurred in 71% and of these 52% were generalised, 37% partial and 11% mixed. 31% had ongoing seizures postoperatively. Headache occurred in 38% (of these 50% had headache and seizures). Focal neurological deficits (FNDs) occurred in 21% (of these 61% had FNDs and seizures). Seizure, as an isolated pre-operative symptom occurred in 48% patients compared to isolated headache in 10% and isolated FNDs in 4%. Anatomically, 58% of lesions were frontal. The seizure spatial frequency was 60% frontal. Histologically, 60% were diffuse astrocytomas and 40% oligodendrogliomas. Furthermore, 71% of oligodendrogliomas and 49% of diffuse astrocytomas had a frontal location. IDH-1 mutation occurred in 80% patients (75% of these had seizures) and of these 66% were frontal. CONCLUSIONS Our analysis confirms a correlation between incidence of seizures, frontal lobar location, histopathological subtype and IDH-1 mutations (p = <0.05

中文翻译：

---

P04.11 WHO II 级胶质瘤的 10 年机构回顾性病例系列与癫痫发作、脑叶位置、组织病理学亚型和 IDH-1 突变的相关性（2010-2020）

背景 对 2010 年 1 月间在神经科学研究所 (INS) 组织诊断为世界卫生组织 (WHO) II 级胶质瘤，即低级别胶质瘤 (LGGM) 的所有患者进行了为期 10 年的回顾性病例系列研究和 2020 年 1 月（注：2016 年之前的世界卫生组织分类）。目的是评估世界卫生组织 (WHO) II 级胶质瘤与癫痫发作症状、脑内肿瘤位置、组织病理学胶质瘤亚型和分子标志物（包括异柠檬酸脱氢酶-1 (IDH-1) 突变）的相关性。材料和方法 我们提取了有关患者临床、放射学、组织学、分子鉴别和功能结果的数据。术前症状仅限于癫痫发作、头痛和局灶性神经功能缺损。结果 84 例患者接受了切除术，平均年龄为 42 岁（范围：21-77 岁）。癫痫发作（注：2017 年之前的国际抗癫痫联盟分类 [ILAE]）发生率为 71%，其中 52% 为全身性癫痫发作，37% 为部分性癫痫发作，11% 为混合性癫痫发作。31% 的患者术后持续癫痫发作。38% 发生头痛（其中 50% 有头痛和癫痫发作）。21% 发生局灶性神经功能缺损 (FND)（其中 61% 有 FND 和癫痫发作）。癫痫发作作为一种孤立的术前症状发生在 48% 的患者中，而孤立的头痛为 10%，孤立的 FND 为 4%。解剖学上，58% 的病变位于额叶。癫痫发作的空间频率为正面的 60%。组织学上，60% 为弥漫性星形细胞瘤，40% 为少突胶质细胞瘤。此外，71% 的少突胶质细胞瘤和 49% 的弥漫性星形细胞瘤位于额叶。IDH-1 突变发生在 80% 的患者中（其中 75% 有癫痫发作），其中 66% 是额叶。结论 我们的分析证实了癫痫发作的发生率、额叶位置、组织病理学亚型和 IDH-1 突变之间的相关性（p = <0.05